VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PLXProtalix BioTherapeutics, Inc.
$2.30$185M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPLXCash Flow

Protalix BioTherapeutics, Inc. (PLX) Cash Flow Statement

30Y historyFree accessUpdated daily

Cash conversion efficiency remains unreliable, evidenced by an OCF/NI ratio that swung from -31.91 in 2025Q2 to 1.20 in 2026Q1, reflecting a business model heavily dependent on non-recurring cash inflows.

PLX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations15.09M-11.99M8.67M-1.32M-25M-10.29M-26.11M-19.36M-7.74M-9.99M-32.1M-24.28M-29.28M-30.65M635K-23.57M-38.46M44.45M-16.02M-10.45M-5.09M-72.47K-168.13K-136.68K-146.59K-789.43K-53.11K-1.41M-909.52K-247.92K-40.57K
Operating CF Margin %--22.74%16.24%-2.01%-52.48%-26.82%-41.51%-35.39%-22.61%-47.41%-348.93%-556.46%-193.15%-266.25%1.84%-281.06%-342.08%11456.7%---3394%-48.32%-39.1%-----39.61%-11.32%--
Operating CF Growth %250.44%-238.26%758.12%94.73%-143.07%60.6%-34.86%-150.04%22.53%68.86%-32.18%17.07%4.48%-4927.24%102.69%38.72%-186.53%377.56%-53.27%-105.24%-6924.49%56.89%-23%6.76%81.43%-1386.46%96.23%-54.82%-266.86%-511.08%-
Net Income15.33M-6.6M2.93M8.31M-14.93M-27.58M-6.52M-18.28M-26.46M-85.28M-29.18M-27.28M-29.94M-27.79M-11.62M-36.53M-29M-31.44M-22.41M-22.48M-9.39M-74.93K-160.07K-140.71K-149.76K-329.17K-105.61K-997.87K-1.15M118.44K131.68K
Depreciation & Amortization58K01.3M1.19M1.09M1.12M1.3M1.62M1.67M1.92M1.98M2.37M3.14M3.54M3.69M3.63M3.13M1.99M1.3M759K502K000000163.2K202.21K00
Stock-Based Compensation-8K03.25M3.45M2.08M2.38M3.13M835K514K337K988K1.8M1.24M4.09M7.75M886K1.28M2.68M3.07M10.85M3.42M0000000000
Deferred Taxes184K0236K-3.09M000-68K-64K39.35M-7.59M1.56M115K142K240K36.87M-617K-218K-3.03M-11.71M-3.46M00000000-32.75K-8.47K
Other Non-Cash Items-1.36M4.71M138K-638K-1.23M3.9M3.12M3.37M3.07M4.57M581K569K1.89M-137K-171K-36.37M377K265K3.05M11.1M3.57M004.25K-150-66.29K-141.3K508.36K-526.47K-343.84K-243.74K
Working Capital Changes-5.72M-10.1M811K-10.54M-12.02M9.9M-27.13M-6.83M13.53M29.1M1.12M-3.3M-5.72M-10.5M741K7.94M-13.64M71.17M2.01M1.04M269K2.46K-8.05K-2183.33K-393.96K193.8K-1.08M561.54K10.23K79.96K
Change in Receivables-9.49M-5.89M2.32M-428K-1.19M-1.03M2.09M188K-3.1M25K-1.13M523K-799K1.9M243K3.89M-6.86M-1.22M636K140K-1.03M0000000000
Change in Inventory-10.97M-4.49M-2.2M-2.24M1.15M-4.87M-4.93M414K-736K-2.59M522K-2.32M1.29M-3.92M-3.76M910K-1.19M00000000000000
Change in Payables5.14M0000002.14M-520K4.9M2.14M-1.87M954K-1.32M2.98M6.15M-1.03M7.78M1.38M903K1.3M0000000000
Cash from Investing2.17M-2.37M4.22M-16.71M-5.04M18.92M-19.95M-883K-591K-1.12M-967K39.39M-1M-2.1M-2.29M-5.87M-7.99M-6.17M-3.7M-2.44M-980K0552.36K-491.48K38.59K1.31M71.37K532.43K-3.85M31.89K-6.32M
Capital Expenditures-455K0-1.28M-1.15M-628K-1.46M-655K-627K-686K-971K-849K-464K-785K-1.89M-2.07M-5.71M-7.86M-6.2M-3.37M-2.33M-842K000000-29.3K-139.99K00
CapEx % of Revenue0.6%3.11%2.4%1.75%1.32%3.8%1.04%1.15%2%4.61%9.23%10.63%5.18%16.42%6.01%68.03%69.86%1596.65%--561.33%------0.82%1.74%--
Acquisitions0000000003K20K3K0000000000000000000
Investments-------------------------------
Other Investing2.62M-2.37M83K-142K593K380K703K-256K95K-148K-118K39.85M-126K-212K-218K2K-137K21K-330K-103K-91K0552.36K60.88K38.59K97.11K226.88K1.62M-3.65M31.89K0
Cash from Financing4.4M9.33M-16.79M24.67M8.24M12.08M46.47M0-4.75M-1.42M19.7M6.63M46K66.89M26.56M20.93M501K293K-51K58.57M16.71M494K0000-35K-6.3K5.97M07.05M
Debt Issued (Net)00-20.42M00-34.12M-215K0-4.75M-1.42M19.68M0066.78M0000000-1M755K000-35K-6.3K-517.03K00
Equity Issued (Net)4.25M9.33M3.63M23.95M8.24M46.2M46.21M00006.1M0025.33M20.65M005K58.67M16.37M8.37M2.55M00000007.05M
Dividends Paid0000000000000000000000000000000
Share Repurchases000000000000000000-56K000000000000
Other Financing153K00712K2K0472K00014K534K46K112K1.23M277K501K293K-56K-104K341K-6.88M0000006.48M00
Net Change in Cash22.25M-4.38M-3.87M6.52M-21.87M20.72M473K-20.02M-13.36M-12.12M-13.09M21.61M-31.63M34.36M25.03M-8.9M-45.37M38.67M-19.22M46.44M10.64M421.52K384.23K-628.16K-108K524.9K-16.73K-882.01K1.2M-216.03K687.89K
Free Cash Flow14.63M-13.63M7.39M-2.47M-25.63M-11.74M-26.76M-19.98M-8.43M-10.96M-32.95M-24.75M-30.07M-32.54M-1.43M-29.27M-46.32M38.26M-19.39M-12.78M-5.93M-72.47K-168.13K-136.68K-146.59K-789.43K-53.11K-1.44M-1.05M-247.92K-40.57K
FCF Margin %19.16%-25.84%13.84%-3.77%-53.8%-30.62%-42.55%-36.54%-24.61%-52.02%-358.16%-567.09%-198.32%-282.66%-4.16%-349.09%-411.94%9860.05%---3955.33%-48.32%-39.1%-----40.43%-13.06%--
FCF Growth %1036.94%-284.4%399.64%90.37%-118.22%56.12%-33.91%-137.13%23.14%66.72%-33.13%17.69%7.61%-2170.97%95.1%36.8%-221.07%297.34%-51.64%-115.47%-8086.27%56.89%-23%6.76%81.43%-1386.46%96.31%-36.96%-323.33%-511.08%-
FCF per Share0.18-0.170.09-0.03-0.53-0.27-0.92-1.35-0.57-0.84-0.32-0.26-0.32-0.35-0.16-0.35-0.570.50-0.26-1.90-0.20-0.00-5.46-0.47-0.50-2.45-0.13-2.76-2.30-0.97-0.19
FCF Conversion (FCF/Net Income)0.95x1.82x2.96x-0.16x1.67x0.37x4.00x1.06x0.29x0.12x1.09x-0.42x0.98x1.10x-0.05x0.65x1.33x-1.41x0.71x0.46x0.54x0.01x0.07x0.97x0.98x2.40x0.50x1.41x0.79x-2.09x-0.31x
Interest Paid000003.41M4.34M000000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Liquidity and milestone dependency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Remains Highly Volatile

As reported in recent financial statements, the relationship between net income and operating cash flow is erratic, with the OCF/NI ratio swinging from -31.91 in 2025Q2 to 1.20 in 2026Q1, suggesting that reported earnings are frequently decoupled from actual cash generation capabilities.

The extreme variance in the OCF/NI ratio indicates that accounting profits are heavily influenced by non-cash items or timing differences rather than core operational efficiency. Investors should interpret this divergence as a signal that the company's earnings quality is currently low and highly sensitive to the timing of milestone recognition.

Free Cash Flow Lacks Consistency

Based on the company's quarterly filings, free cash flow margins have fluctuated wildly between -53.0% and 63.0% over the last ten quarters, reflecting a business model that struggles to maintain a predictable cash-generative trajectory amidst its ongoing commercial transition and reliance on lumpy partnership payments.

The inability to sustain positive free cash flow suggests that the firm remains in a capital-intensive phase where operational success is not yet translating into reliable liquidity. This volatility warrants caution, as it implies that the company may remain dependent on external financing to bridge gaps between major revenue events.

Working Capital Swings Drive Liquidity

According to the provided cash flow data, working capital changes have been a primary driver of cash flow volatility, with quarterly fluctuations ranging from a $7.1M outflow in 2025Q3 to an $8.1M inflow in 2024Q1, highlighting the significant impact of inventory and receivable timing.

These sharp swings in working capital suggest that the company's cash position is highly vulnerable to the procurement cycles of its primary partners. Such reliance on the timing of bulk shipments implies that liquidity management is likely reactive rather than proactive, which may pose risks during periods of operational disruption.

Cash Flow Obscures Operational Realities

Analysis of the cash flow statement reveals that stock-based compensation and depreciation adjustments frequently mask the underlying cash burn, as evidenced by the persistent negative operating cash flow observed in several quarters despite the company's efforts to reach commercial scale through its ProCellEx platform.

The reliance on non-cash adjustments to bolster the appearance of cash flow suggests that the core business is not yet self-funding. Investors should monitor whether the company can reduce its reliance on these accounting adjustments as Elfabrio commercialization matures, as current trends indicate a continued need for external capital.

PLX — Frequently Asked Questions

Quick answers to the most common questions about buying PLX stock.

How much cash does Protalix BioTherapeutics, Inc. (PLX) generate from operations?

Protalix BioTherapeutics, Inc. (PLX) generated $-12.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Protalix BioTherapeutics, Inc.'s free cash flow?

Protalix BioTherapeutics, Inc. (PLX) reported negative free cash flow of $13.6M in 2025, indicating capital requirements exceeded cash from operations.

What is Protalix BioTherapeutics, Inc.'s capital expenditure (CapEx)?

Protalix BioTherapeutics, Inc. (PLX) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.